VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

作者：Jianjun Gao, John F. Ward, Curtis A. Pettaway, Lewis Z. Shi, Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou, Patricia Troncoso, James P. Allison, Christopher J. Logothetis, Ignacio I. Wistuba, Manuel A. Sepúlveda, Jingjing Sun, Jennifer A. Wargo, Jorge Blando, Padmanee Sharma · 发表于：Nature Medicine · 年份：2017 · DOI：10.1038/nm.4308 · 被引用次数：599 · 研究领域：Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、Prostate Cancer Treatment and Research